NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance
Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance.
See our latest analysis for Arcutis Biotherapeutics.
The latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have...